<DOC>
	<DOC>NCT00668343</DOC>
	<brief_summary>Patient with relapsing remitting multiple sclerosis taking avonex are included in this double blind randomized control trial. Simvastatin is compared to placebo. end points of edss , total attack, new enhancing lesion and newt2 lesion in mri is evaluated as end point.</brief_summary>
	<brief_title>Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>1. edss&lt;5 2. &gt;=1 attack in last year 1. &gt;2 attacks in study 2. drug complication</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>edss attack</keyword>
</DOC>